Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Equity and Cancer Survival Among Veterans Health Administration Patients: A Systematic Review and Meta-Analysis.

JAMA network open·2026

Same author

Phenotyping Prostate Cancer in a National Health System Using Large Language Models.

JCO clinical cancer informatics·2026

Same author

Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Development and External Validation of a Machine Learning-Based Risk Classification Score for Prostate Cancer-Specific Cardiovascular Risk.

JCO oncology practice·2026

Same author

Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer.

Clinical and translational radiation oncology·2026

Same author

Germline polygenic score for prostate cancer aggressiveness.

medRxiv : the preprint server for health sciences·2026

Same journal

Personalizing N-of-1 Trial Results to Facilitate Decision-Making.

JAMA network open·2026

Same journal

Prostate Cancer Screening-Where We've Been, Where We Are, and What Comes Next.

JAMA network open·2026

Same journal

Comparison of Care Cascade Outcome Measures for Hepatitis C Among Insured US Adults.

JAMA network open·2026

Same journal

At-Home Transvaginal Pelvic Ultrasonography and Image Quality in Premenopausal Women: A Nonrandomized Clinical Trial.

JAMA network open·2026

Same journal

Aerobic Exercise and Subthreshold Depressive Symptoms in Adolescents: Secondary Analysis of a Randomized Clinical Trial.

JAMA network open·2026

Same journal

Prefrontal Transcranial Pulse Stimulation for Major Depressive Disorder: A Randomized Clinical Trial.

JAMA network open·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans.

Mehrnaz Siavoshi^1,2, Stephen Frochen^1,2, Mary Fakunle²

¹Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California.

JAMA Network Open

|July 6, 2026

Summary

This summary is machine-generated.

Optimizing prostate cancer (PC) screening, particularly for older men and those with longer intervals between prostate-specific antigen (PSA) tests, could reduce metastatic PC incidence. Shorter screening intervals for younger men show promise in lowering metastatic PC rates.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Related Experiment Videos

Last Updated: Jul 7, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Area of Science:

Urology
Oncology
Public Health

Background:

Metastatic prostate cancer (PC) incidence is rising in US men, influenced by evolving prostate-specific antigen (PSA) screening guidelines.
Contemporary PSA screening practices in large healthcare systems require further examination.

Purpose of the Study:

To describe and analyze current PSA testing patterns.
To investigate the association between PSA screening practices and metastatic PC incidence.

Main Methods:

This cohort study analyzed data from 103,067 veterans undergoing prostate needle biopsy (PNB) between 2015-2023.
PSA test intervals and age at first PSA were categorized.
Multivariable Cox models assessed the risk of metastatic PC adjusted for covariates.

Main Results:

Older age at first PSA and longer screening intervals were associated with a higher risk of metastatic PC.
Men aged 60+ with longer intervals had the highest risk.
Younger men (<50) with shorter intervals had the lowest risk of metastatic PC.

Conclusions:

Few veterans exhibited optimal screening profiles concerning metastatic PC risk.
There is a significant opportunity to optimize PSA screening strategies.
Adjusting screening frequency and age can potentially reduce metastatic PC diagnoses.